In addition, in combination with doxorubicin, RL2 can also promote doxorubicin-induced caspase-3/7 activity in breast cancer cells, thereby increasing the level of apoptosis and amplifying the antitumor effects of doxorubicin [129]. Here, CASP3 is linked to breast cancer.